These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24196512)

  • 21. Remarks delivered at the Food and Drug Law Institute's 48th Annual Conference.
    Enzi MB
    Food Drug Law J; 2005; 60(2):103-6. PubMed ID: 16097090
    [No Abstract]   [Full Text] [Related]  

  • 22. Enforcement actions involving Medicaid fraud and abuse, 1996-2009.
    Qureshi ZP; Liu Y; Sartor O; Chu YH; Bennett CL
    Arch Intern Med; 2011 Apr; 171(8):785-7. PubMed ID: 21518950
    [No Abstract]   [Full Text] [Related]  

  • 23. A millstone in the uphill battle for credibility.
    Czap A
    Altern Med Rev; 2001 Feb; 6(1):3. PubMed ID: 11207452
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmaceutical industry wins "round one" in protections against product liability claims.
    Gatty B
    Hosp Formul; 1995 Apr; 30(4):238, 237. PubMed ID: 10141868
    [No Abstract]   [Full Text] [Related]  

  • 25. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 26. Corporate compliance programs for FDA-regulated companies: incentives for their development and the impact of the federal sentencing guidelines for organizations.
    Freyer DH
    Food Drug Law J; 1996; 51(2):225-42. PubMed ID: 11820200
    [No Abstract]   [Full Text] [Related]  

  • 27. Punishing health care fraud--is the GSK settlement sufficient?
    Outterson K
    N Engl J Med; 2012 Sep; 367(12):1082-5. PubMed ID: 22970920
    [No Abstract]   [Full Text] [Related]  

  • 28. Opposition in search of a rationale: the case for Food and Drug Administration regulation.
    Myers ML
    Tob Control; 2004 Dec; 13(4):441-3. PubMed ID: 15564634
    [No Abstract]   [Full Text] [Related]  

  • 29. Recent case developments in health law. False Claims Act: the right treatment for off-label marketing?
    Wang S
    J Law Med Ethics; 2010; 38(3):708-13. PubMed ID: 20880253
    [No Abstract]   [Full Text] [Related]  

  • 30. Reforming direct-to-consumer advertising.
    Liang BA; Mackey T
    Nat Biotechnol; 2011 May; 29(5):397-400. PubMed ID: 21552236
    [No Abstract]   [Full Text] [Related]  

  • 31. Free rein for drug ads? A slowdown in FDA review has left consumers more vulnerable to misleading messages.
    Consum Rep; 2003 Feb; 68(2):33-7. PubMed ID: 12516586
    [No Abstract]   [Full Text] [Related]  

  • 32. Disease management and antikickback regulations.
    Kozma CM
    Manag Care Interface; 2003 Dec; 16(12):34-5. PubMed ID: 14750462
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug maker's efforts to compete in lucrative insulin market are under scrutiny.
    Harris G; Pear R
    N Y Times Web; 2006 Jan; ():A14. PubMed ID: 16453399
    [No Abstract]   [Full Text] [Related]  

  • 34. The Federal Trade Commission's regulation of weight-loss advertising claims.
    Correia E
    Food Drug Law J; 2004; 59(4):585-94. PubMed ID: 15875353
    [No Abstract]   [Full Text] [Related]  

  • 35. The need for FDA regulation of tobacco products.
    Kennedy EM
    Yale J Health Policy Law Ethics; 2002; 3(1):101-8. PubMed ID: 12825428
    [No Abstract]   [Full Text] [Related]  

  • 36. Beyond food and evil.
    Chen J
    Duke Law J; 2007 Apr; 56(6):1581-6. PubMed ID: 17679180
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA warns Bayer about illegally marketing two over the counter products containing aspirin.
    Kmietowicz Z
    BMJ; 2008 Nov; 337():a2402. PubMed ID: 18984638
    [No Abstract]   [Full Text] [Related]  

  • 38. Prescription drug advertising--should states regulate what is false and misleading?
    Shaeffer J
    Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454
    [No Abstract]   [Full Text] [Related]  

  • 39. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 40. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.